Microcapsule-Based Dose-Dependent Regulation of the Lifespan and Behavior of Adipose-Derived MSCs as a Cell-Mediated Delivery System: In Vitro Study.
cell viability
division
human adipose-derived MSCs
layer-by-layer technique
migration
phagocytosis
polyelectrolyte microcapsules
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
24 Dec 2022
24 Dec 2022
Historique:
received:
29
11
2022
revised:
20
12
2022
accepted:
21
12
2022
entrez:
8
1
2023
pubmed:
9
1
2023
medline:
11
1
2023
Statut:
epublish
Résumé
The development of “biohybrid” drug delivery systems (DDS) based on mesenchymal stem/stromal cells (MSCs) is an important focus of current biotechnology research, particularly in the areas of oncotheranostics, regenerative medicine, and tissue bioengineering. However, the behavior of MSCs at sites of inflammation and tumor growth is relevant to potential tumor transformation, immunosuppression, the inhibition or stimulation of tumor growth, metastasis, and angiogenesis. Therefore, the concept was formulated to control the lifespan of MSCs for a specific time sufficient for drug delivery to the target tissue by varying the number of internalized microcontainers. The current study addressed the time-dependent in vitro assessment of the viability, migration, and division of human adipose-derived MSCs (hAMSCs) as a function of the dose of internalized polyelectrolyte microcapsules prepared using a layer-by-layer technique. Polystyrene sulfonate (PSS)—poly(allylamine hydrochloride) (PAH)-coated spherical micrometer-sized (diameter ~2−3 µm) vaterite (CaCO3) microcapsules (PAH-PSS)6 with the capping PSS layer were prepared after dissolution of the CaCO3 core template. The Cell-IQ phase contrast imaging results showed that hAMSCs internalized all (PAH-PSS)6 microcapsules saturating the intercellular medium (5−90 particles per cell). A strong (r > 0.7) linear dose-dependent and time-dependent (up to 8 days) regression was observed between the in vitro decrease in cell viability and the number of internalized microvesicles. The approximate time-to-complete-death of hAMSCs at different concentrations of microcapsules in culture was 428 h (1:5 ratio), 339 h (1:10), 252 h (1:20), 247 h (1:45), and 170 h (1:90 ratio). By varying the number of microcontainers loaded into the cells (from 1:10 to 1:90), a dose-dependent exponential decrease in both the movement rate and division rate of hAMSCs was observed. A real-time cell analysis (RTCA) of the effect of (PAH-PSS)6 microcapsules (from 1:5 to 1:20) on hAMSCs also showed a dose- and time-dependent decrease in cell longevity after a 50h study at ratios of 1:10 and 1:20. The incorporation of microcapsules (1:5, 1:20, and 1:45) resulted in a dose-dependent increase in 24−48 h secretion of GRO-α (CXCL1), MIF, and SDF-1α (CXCL12) chemokines in hAMSC culture. In turn, the normalization or inhibition of chemokine secretion occurred after 72 h, except for MIF levels below 5−20 microcapsules, which were internalized by MSCs. Thus, the proposed concept of controlling the lifespan of MSC-based DDS using a dose of internalized PAH-PSS microcapsules could be useful for biomedical applications. (PAH-PSS)6 microcapsule ratios of 1:5 and 1:10 have little effect on the lifespan of hAMSCs for a long time (up to 14−18 days), which can be recommended for regenerative therapy and tissue bioengineering associated with low oncological risk. The microcapsule ratios of 1:20 and 1:45 did not significantly restrict the migratory activity of hAMSCs-based DDS during the time interval required for tissue delivery (up to 4−5 days), followed by cell death after 10 days. Therefore, such doses of microcapsules can be used for hAMSC-based DDS in oncotheranostics.
Identifiants
pubmed: 36613737
pii: ijms24010292
doi: 10.3390/ijms24010292
pmc: PMC9820487
pii:
doi:
Substances chimiques
Capsules
0
Polyelectrolytes
0
Calcium Carbonate
H0G9379FGK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : State Assignment of Immanuel Kant Baltic Federal University
ID : FZWM-2020-0010
Références
Clin Implant Dent Relat Res. 2006;8(1):32-8
pubmed: 16681491
J Nanobiotechnology. 2017 Mar 29;15(1):24
pubmed: 28356160
Aging (Albany NY). 2019 Dec 27;11(24):12641-12660
pubmed: 31881006
Cytotherapy. 2013 Jun;15(6):641-8
pubmed: 23570660
Stem Cells Transl Med. 2018 Sep;7(9):651-663
pubmed: 30070053
Macromol Biosci. 2017 Jan;17(1):
pubmed: 27925398
J Am Chem Soc. 2018 Jan 31;140(4):1199-1202
pubmed: 29281277
Ann Plast Surg. 2014 May;72(5):589-93
pubmed: 23636113
Front Immunol. 2020 Jun 04;11:952
pubmed: 32582148
Biomed Mater Eng. 2013;23(4):299-309
pubmed: 23798651
J Bone Miner Metab. 2021 Mar;39(2):126-138
pubmed: 33079278
ACS Appl Mater Interfaces. 2019 Apr 10;11(14):13091-13104
pubmed: 30883080
Colloids Surf B Biointerfaces. 2009 Apr 1;70(1):114-23
pubmed: 19162453
Cancer Lett. 2015 Apr 10;359(2):335-43
pubmed: 25641338
Expert Opin Drug Deliv. 2017 May;14(5):583-587
pubmed: 28121205
Cell Prolif. 2020 Jan;53(1):e12712
pubmed: 31730279
Cancer Lett. 2011 Jun 1;305(1):8-20
pubmed: 21396770
Theranostics. 2015 Apr 27;5(8):863-81
pubmed: 26000058
Acta Pharm Sin B. 2016 Jul;6(4):261-7
pubmed: 27471667
J Phys Chem B. 2006 Aug 10;110(31):15345-52
pubmed: 16884254
Biotechnol Adv. 2018 Jul - Aug;36(4):986-1002
pubmed: 29524464
Stem Cell Res Ther. 2014 May 06;5(3):63
pubmed: 24887516
Adv Healthc Mater. 2018 Feb;7(3):
pubmed: 29193876
J Cell Physiol. 1986 Dec;129(3):283-8
pubmed: 3782308
Mol Pharm. 2012 Sep 4;9(9):2698-709
pubmed: 22862421
Tissue Eng. 2001 Apr;7(2):211-28
pubmed: 11304456
Front Cell Dev Biol. 2021 Jul 12;9:686453
pubmed: 34322483
Neurotherapeutics. 2011 Oct;8(4):744-52
pubmed: 21901585
Stem Cells Dev. 2009 Apr;18(3):511-9
pubmed: 18624673
Biomaterials. 2006 May;27(14):2820-8
pubmed: 16430958
Circ Res. 2009 Feb 13;104(3):398-402
pubmed: 19096027
Biotechnol Prog. 2005 May-Jun;21(3):918-25
pubmed: 15932274
Chem Mater. 2012 Mar 13;24(5):854-869
pubmed: 25076811
J R Soc Interface. 2010 Dec 6;7 Suppl 6:S753-63
pubmed: 20880852
Tissue Eng Part A. 2014 Jan;20(1-2):197-209
pubmed: 23980822
Nature. 2007 Oct 4;449(7162):557-63
pubmed: 17914389
Biomaterials. 2012 May;33(14):3639-50
pubmed: 22364729
Expert Opin Drug Deliv. 2016 Jun;13(6):789-98
pubmed: 26986001
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Biotechnol Bioeng. 2004 Sep 20;87(6):723-33
pubmed: 15329930
Adv Mater. 2013 Dec 23;25(48):6945-50
pubmed: 24027123
J R Soc Interface. 2014 Dec 6;11(101):20141027
pubmed: 25339691
Int J Nanomedicine. 2018 Apr 05;13:2079-2091
pubmed: 29670351
Cancer Lett. 2017 Sep 10;403:271-279
pubmed: 28642171
J Exp Clin Cancer Res. 2020 Feb 22;39(1):40
pubmed: 32087737
Biotechnol Prog. 2020 Nov;36(6):e3025
pubmed: 32410328
J Mater Chem B. 2016 Dec 7;4(45):7270-7282
pubmed: 32263729
Sci Rep. 2019 Dec 27;9(1):20003
pubmed: 31882795
Stem Cells. 2008 May;26(5):1275-87
pubmed: 18292209
Bioeng Transl Med. 2021 Dec 24;7(2):e10278
pubmed: 35600644
ACS Nano. 2011 Sep 27;5(9):7462-70
pubmed: 21854047
Nano Lett. 2013 Jul 10;13(7):3248-55
pubmed: 23786263
Anticancer Agents Med Chem. 2017 Nov 24;17(11):1578-1585
pubmed: 28356007
Gene Ther. 2008 May;15(10):739-52
pubmed: 18369324
J Pharmacol Exp Ther. 2019 Aug;370(2):231-241
pubmed: 31175219
J Mater Chem B. 2016 Jan 14;4(2):245-256
pubmed: 32263367
J Plast Reconstr Aesthet Surg. 2013 May;66(5):712-9
pubmed: 23357708
Transplant Proc. 2007 Mar;39(2):573-6
pubmed: 17362785
Cytotherapy. 2017 Jan;19(1):19-27
pubmed: 27765601
Biomed Eng Lett. 2020 Mar 13;10(2):259-273
pubmed: 32477611
Angew Chem Int Ed Engl. 2020 Mar 27;59(14):5438-5453
pubmed: 31657113
Biosensors (Basel). 2015 Apr 16;5(2):199-222
pubmed: 25893878
Materials (Basel). 2020 Oct 02;13(19):
pubmed: 33023124
Eur J Pharm Sci. 2017 Jan 1;96:115-128
pubmed: 27496050
Methods. 2015 Aug;84:3-16
pubmed: 25770356
Adv Healthc Mater. 2016 Dec;5(24):3182-3190
pubmed: 27860430
J Vis Exp. 2016 Mar 07;(109):
pubmed: 27023147
ACS Nano. 2019 Apr 23;13(4):4631-4639
pubmed: 30875468
J Mater Sci Mater Med. 2004 Apr;15(4):493-6
pubmed: 15332623
Front Bioeng Biotechnol. 2022 Feb 24;10:796111
pubmed: 35284410